NovLC inhibits the proliferation of liver cancer cells (G1 arrest) by increasing Reactive Oxygen Species with a mechanism different from existing medications.
Therefore, unlike the existing medication, Tyrosine Kinase Inhibitor, the risk of developing resistance is relatively low.
Also, NovLC can be administered in combination with Tyrosine Kinase Inhibitor and additional effects of combined administration can be expected.
In fact, NovMetaHealth identified that when NovLC and Sorafenib (first-line therapy for liver cancer) were administered in combination, it overcomes the resistance of Sorafenib and reduces tumor.